Topics:
Rheumatology • General Rheumatology • Polymyalgia rheumatica • Journal Club ft. NEJM publications
How will you approach drug sequencing in patients with PMR given the SAPHYR data?
Will you initiate sarilumab as a first steroid sparing agent or will you still pursue a DMARD such as methotrexate before initiating sarilumab? To what extent do you think other IL-6 inhibitors will play a role?
Answer from: at Community Practice
The SAPHYR study enrolled patients with PMR who relapsed while tapering prednisone at daily doses equal to or greater than 7.5 mg. One group of patients received sarilumab 200 mg every 2 weeks along with a 14-week prednisone taper and another group of patients received a placebo along with a 52-week...
Sign in or Register to read more
Answer from: at Academic Institution
This is a great question and one where we need more data to guide clinical practice. As with any new therapy, there will be a slow uptake in practice and we will need to learn more about the use of IL-6 inhibitors in a real-world setting. To date, IL-6 inhibitors are only being used in a minority of...